VilosenВилозен
A nonprotein extract from animal thymus, also spelled Vilozen, studied in historical human immune research.
What the studies found
Observational study · 1990
The effect of vilozen on the immune status of bronchial asthma patients
- Reported response
- Immune correction and clinical improvement described in atopic-associated asthma; no response rate supplied
The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.
Study notes · methods, sources and limitations
Participants or model 163 bronchial-asthma patients underwent immune assessment; the abstract does not specify how many received Vilosen.
Design 163 bronchial-asthma patients underwent immune assessment; the abstract does not specify how many received Vilosen.
- Assessed population
- 163 patients; treated subset not stated
Important limitations
- The 163 assessed patients are not a verified treatment-arm count. Background treatment and uncontrolled selection prevent attributing clinical benefit to the extract alone.
Vrachebnoe delo 1990 · Journal publication
Comparison in people · 1993
The immunomodulating effect of vilozen and splenin in the treatment of patients with acute and chronic toxic-allergic hepatitis
- Combination result
- Faster clinical-index and immune-homeostasis normalization reported; no numerical effect supplied
Vilosen plus Splenin was reported to speed clinical and immune normalization when added to usual hepatitis treatment. Of 181 patients assessed, 60 are explicitly described as receiving the combination.
Study notes · methods, sources and limitations
Participants or model 65 acute and 116 chronic toxic-allergic hepatitis patients examined; 20 acute and 40 chronic patients received add-on Vilosen plus Splenin.
Design 65 acute and 116 chronic toxic-allergic hepatitis patients examined; 20 acute and 40 chronic patients received add-on Vilosen plus Splenin.
- Explicitly treated subset
- 20 acute + 40 chronic patients
- Treatment course
- 10–15 days; Vilosen plus intramuscular Splenin and usual care
Important limitations
- No numerical between-group outcome or allocation method is supplied. Splenin and background therapy prevent isolating Vilosen. The abstract’s intranasal/sublingual dose wording is ambiguous.
Likars'ka sprava 1993 · Journal publication
Observational study · 1996
The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases
- Clinical findings
- Improved clinical measures and longer remission reported; no duration supplied
The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.
Study notes · methods, sources and limitations
Participants or model 93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.
Design 93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.
- Study population
- 93 patients
Important limitations
- No isolated Vilosen arm or numerical clinical comparison is described.
Likars'ka sprava 1996 · Journal publication
About Vilosen
Identity / background source ↗
Research background
Animal-thymus nonprotein extract reported in asthma, hepatitis and immune research. Historical clinical reports include combinations with Splenin; it is distinct from synthetic Vilon.
- Compound class
- Peptide / preparation research
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- See individual study records
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
Historical adjunctive reports; treated subsets and comparator details vary
Study methods
Three original clinical abstracts; no isolated effect established for combination regimens
Independent replication
Related reports are not automatically independent evidence
Source access
Primary-publication records linked; full-text versus abstract review shown per source
Safety evidence
Clinical safety, product equivalence and interactions not established by this collection
Open a topic for the evidence assessment.
Findings by study
Observational study · 1990
The effect of vilozen on the immune status of bronchial asthma patients
The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.
Study notes and original source
The effect of vilozen on the immune status of bronchial asthma patients
Native nonprotein animal-thymus extract; not synthetic Vilon · Journal publication
Kogosova LS, Kovalenko NN, Strafun OV, Markov AE · Vrachebnoe delo 1990
The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.
Results and tables
Reported findings and study design
The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.
163 bronchial-asthma patients underwent immune assessment; the abstract does not specify how many received Vilosen.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Reported response | Immune correction and clinical improvement described in atopic-associated asthma; no response rate supplied | |
| Assessed population | 163 patients; treated subset not stated |
The 163 assessed patients are not a verified treatment-arm count. Background treatment and uncontrolled selection prevent attributing clinical benefit to the extract alone.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 163 bronchial-asthma patients underwent immune assessment; the abstract does not specify how many received Vilosen.
- Source reviewed
- Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
- The 163 assessed patients are not a verified treatment-arm count. Background treatment and uncontrolled selection prevent attributing clinical benefit to the extract alone.
Reviewed 2026-11-01.
Comparison in people · 1993
The immunomodulating effect of vilozen and splenin in the treatment of patients with acute and chronic toxic-allergic hepatitis
Vilosen plus Splenin was reported to speed clinical and immune normalization when added to usual hepatitis treatment. Of 181 patients assessed, 60 are explicitly described as receiving the combination.
Study notes and original source
The immunomodulating effect of vilozen and splenin in the treatment of patients with acute and chronic toxic-allergic hepatitis
Thymus extract plus separate spleen-derived preparation · Journal publication
Frolov VM, Peresadin NA, Vysotskiĭ IIu, Tishchenko AN, Pinskiĭ LL · Likars'ka sprava 1993
Vilosen plus Splenin was reported to speed clinical and immune normalization when added to usual hepatitis treatment. Of 181 patients assessed, 60 are explicitly described as receiving the combination.
Results and tables
Reported findings and study design
Vilosen plus Splenin was reported to speed clinical and immune normalization when added to usual hepatitis treatment. Of 181 patients assessed, 60 are explicitly described as receiving the combination.
65 acute and 116 chronic toxic-allergic hepatitis patients examined; 20 acute and 40 chronic patients received add-on Vilosen plus Splenin.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Combination result | Faster clinical-index and immune-homeostasis normalization reported; no numerical effect supplied | |
| Explicitly treated subset | 20 acute + 40 chronic patients | |
| Treatment course | 10–15 days; Vilosen plus intramuscular Splenin and usual care |
No numerical between-group outcome or allocation method is supplied. Splenin and background therapy prevent isolating Vilosen. The abstract’s intranasal/sublingual dose wording is ambiguous.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 65 acute and 116 chronic toxic-allergic hepatitis patients examined; 20 acute and 40 chronic patients received add-on Vilosen plus Splenin.
- Source reviewed
- Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
- No numerical between-group outcome or allocation method is supplied. Splenin and background therapy prevent isolating Vilosen. The abstract’s intranasal/sublingual dose wording is ambiguous.
Reviewed 2026-11-01.
Observational study · 1996
The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases
The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.
Study notes and original source
The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases
Thymus extract combined with Splenin · Journal publication
Petrunia AM, Enenko IuA · Likars'ka sprava 1996
The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.
Results and tables
Reported findings and study design
The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.
93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Clinical findings | Improved clinical measures and longer remission reported; no duration supplied | |
| Study population | 93 patients |
No isolated Vilosen arm or numerical clinical comparison is described.
Source for these results ↗ · Reviewed 2026-11-01
- Population / setting
- 93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.
- Source reviewed
- Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
- No isolated Vilosen arm or numerical clinical comparison is described.
Reviewed 2026-11-01.
Animal research · 1994
[Radiation protective effect of low molecular weight thymus preparations].
The abstract discusses low-molecular-weight thymic preparations in radiation injury; it does not provide enough methods to establish a human controlled study.
Study notes and original source
[Radiation protective effect of low molecular weight thymus preparations].
Preparation-specific research; no equivalence inferred
Baraboĭ VA, Ialkut SI, Savtsova ZD, Zinchenko VA, Zhukova VM, Zaritskaia MIu. · Radiatsionnaia biologiia, radioecologiia
The abstract discusses low-molecular-weight thymic preparations in radiation injury; it does not provide enough methods to establish a human controlled study.
- Population / setting
- See original report; human, animal and laboratory components must be distinguished.
- Source reviewed
- Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed. Study type is based on the database record and abstract, where available.
Study limitations
- The abstract leaves the preparation and study methods unclear.
- Related publications may share experiments; source count is not independent-study count.
Reviewed 2026-10-02.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗